Drug Approval | February 10, 2022
USFDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
Adds five years of market exclusivity on approval
Adds five years of market exclusivity on approval
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction
The vaccine will be priced at Rs. 265 per dose and the applicator being offered at Rs. 93 per dose excluding GST
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
It would be the first protein-based alternative available in Israel
SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Subscribe To Our Newsletter & Stay Updated
